https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=17934551&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09 179345512011111020211020
1523-5998942007Primary care companion to the Journal of clinical psychiatryPrim Care Companion J Clin PsychiatryDuloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study.271279271-9In placebo-controlled clinical trials, duloxetine has been shown to be effective and well-tolerated in patients with major depressive disorder (MDD). However, patients in registration trials may not be representative of patients in clinical practice. This study sought to assess the effectiveness, safety, and tolerability of duloxetine in diverse populations of outpatients with MDD.This open-label study recruited out-patients ≥ 18 years of age with DSM-IV MDD in primary care or psychiatric practice settings and treated them with duloxetine 60 mg q.d. for 7 weeks. Primary outcome measures were (1) the physicianrated Clinical Global Impressions-Severity of Illness scale, (2) the patient-rated 28-item Somatic Symptom Inventory (SSI-28) average, and (3) the patient-rated 16-item Quick Inventory of Depressive Symptomatology-Self Report. Quality of life, disability, and vital signs also were assessed. The first patient visit was August 16, 2004. The last patient visit was January 7, 2005.Of 3543 outpatients enrolled, 3431 received at least 1 dose of duloxetine, of whom 71.4% completed the study. Most patients were Caucasian (90.8%) and female (75.4%); mean age was 48 years. Duloxetine significantly (p < .001) improved all efficacy measures in all treated patients as well as in subgroups based on gender, ethnic origin, age, and patient care setting. Except for the SSI-28 average, all the efficacy measures were in favor of female gender and primary care subgroups. Overall, 10.8% of patients discontinued due to adverse events.Duloxetine 60 mg q.d. was effective, regardless of gender, ethnic origin, age, and patient care settings, in this 7-week open-label study and was well-tolerated in a diverse population of outpatients with MDD.ClinicalTrials.gov identifier NCT00479726.WohlreichMadelaine MMMLilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana, USA. mwmd@lilly.comWiltseCurtis GCGDesaiahDurisalaDYeWenyuWRobinsonRebecca LRLKroenkeKurtKKornsteinSusan GSGGreistJohn HJHengClinicalTrials.govNCT00479726Journal Article
United StatesPrim Care Companion J Clin Psychiatry1008874101523-5998200612182007228200710169020071016912007101690200711ppublish17934551PMC201884110.4088/pcc.v09n0404Roy-Byrne PP, Sherbourne CD, and Craske MG. et al. Moving treatment research from clinical trials to the real world. Psychiatr Serv. 2003 54:327–332.12610239Bymaster FP, Dreshfield-Ahmed LJ, and Threlkeld PG. et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001 25:871–880.11750180Detke MJ, Lu Y, Goldstein DJ.. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308–315.12000204Detke MJ, Lu Y, and Goldstein DJ. et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002 36:383–390.12393307Goldstein DJ, Mallinckrodt C, and Lu Y. et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002 63:225–231.11926722Goldstein DJ, Lu Y, and Detke MJ. et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004 24:389–399.15232330Wohlreich MM, Martinez JM, and Mallinckrodt CH. et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol. 2005 25:552–560.16282837Rollman BL, Hanusa BH, and Belnap BH. et al. Race, quality of depression care, and recovery from a depression in primary care setting. Gen Hosp Psychiatry. 2002 24:381–390.12490339Gilmer WS, Trivedi MH, and Rush AJ. et al. Factors associated with chronic depressive episodes: a primary report from the STAR-D project. Acta Psychiatr Scand. 2005 112:425–433.16279871Kales HC, Neighbors HW, and Blow FC. et al. Race, gender, and psychiatrists' diagnosis and treatment of major depression among elderly patients. Psychiatr Serv. 2005 56:721–728.15939950Trivedi MH, Rush AJ, and Wisniewski SR. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 163:28–40.16390886Sherbourne C, Schoenbaum M, and Wells KB. et al. Characteristics, treatment patterns, and outcomes of persistent depression despite treatment in primary care. Gen Hosp Psychiatry. 2004 26:106–114.15038927Corey-Lisle PK, Nash R, and Stang P. et al. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med. 2004 164:1197–1204.15197045Rush AJ, Bose A.. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety. 2005;21:26–32.15786487Nemeroff CB, Schatzberg AF, and Goldstein DJ. et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002 36:106–132.12858150American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association. 1994Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, Md: National Institute of Mental Health (NIMH), Psychophar-macology Research Branch. 1976 217–222. 313–331.Barsky AJ, Wyshak G, Klerman GL.. Hypochondriasis: an evaluation of the DSM-III criteria in medical outpatients. Arch Gen Psychiatry. 1986;43:493–500.3964028Rush AJ, Trivedi MH, and Ibrahim HM. et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 54:573–583.12946886Endicott J, Nee J, and Harrison W. et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993 29:321–326.8290681Sheehan DV, Harnett-Sheehan K, and Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996 11suppl 3. 89–95.8923116Rosenbaum PR, Rubin DB.. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516–524.Lunceford JK, Davidian M.. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23:2937–2960.15351954Kornstein SG, Wohlreich MM, and Mallincrodt CH. et al. Duloxetine efficacy for major depressive disorder in male vs female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry. 2006 67:761–770.16841626Wohlreich MW, Mallinckrodt CH, and Watkin JG. et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatrics. 2004 4:11–20.PMC54456115585058Lewis-Fernandez R, Blanco C, and Mallincrodt CH. et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in US Hispanic and majority Caucasian patients. J Clin Psychiatry. 2006 67:1379–1390.17017824Bailey RK, Mallincrodt CH, and Wohlreich MM. et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc. 2006 98:437–447.PMC257612316573311Bair MJ, Robinson RL, and Eckert GJ. et al. Impact of pain on depression treatment response in primary care. Psychosom Med. 2004 66:17–22.14747633Cuffel BJ, Azocar F, and Tomlin M. et al. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry. 2003 64:397–402.12716239Swindle RW Jr, Cronkite RC, Moos RH.. Risk factors for sustained nonremission of depressive symptoms: a 4-year follow-up. J Nerv Ment Dis. 1998;186:462–469.9717863Kroenke K, Spitzer RL, and Williams JB. et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med. 1994 3:774–779.7987511Gerber PD, Barrett JE, and Barrett JA. et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Med. 1992 7:170–173.1487765Kroenke K.. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Res. 2006;60:335–339.16581354Bair MJ, Robinson RL, and Katon W. et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003 163:2433–2445.14609780Fava M, Mallinckrodt CH, and Detke MJ. et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry. 2004 65:521–530.15119915Karp JF, Scott J, and Houck P. et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry. 2005 66:591–597.15889945Thomas L, Mulsant BH, and Solano FX. et al. Response speed and rate of remission in primary and specialty care of elderly patients with depression. Am J Geriatr Psychiatry. 2002 10:583–591.12213693Robinson RL, Long SR, and Chang S. et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm. 2006 12:43–54.PMC1043764816420107Shasha M, Lyons JS, and O'Mahoney MT. et al. Serotonin reuptake inhibitors and the adequacy of antidepressant treatment. Int J Psychiatry Med. 1997 27:83–92.9565716Vergouwen ACM, Bakker A, and Katon WJ. et al. Improving adherence to antidepressants: a systematic review of interventions. J Clin Psychiatry. 2003 64:1415–1420.14728101Wells KB.. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156:5–10.9892291Zimmerman M, Chelminski I, Posternak MA.. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162:1370–1372.15994721Keefe RS, Mohs RC, and Bilder RM. et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull. 2003 29:45–55.12908660